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Objective: To determine whether long-term dexmedetomidine dosing is associated with lower opioid and benzodiazepine use without risk of significant hemodynamic changes and/or withdrawal. Design: Retrospective, observational study. Setting: PICU, cardiovascular ICU, and neonatal ICU in a single, tertiary care, academic children's hospital. Subjects: We included all patients less than or equal to 21 years old, who received dexmedetomidine for greater than or equal to 72 hours from December 2008 to December 2010 resulting in a 98-subject cohort. Interventions: None.
Measurement and Main Results:
The median duration of dexmedetomidine use was 141 hours. A decrease in systolic blood pressure and heart rate was seen after initiation of dexmedetomidine. After dexmedetomidine was discontinued, systolic blood pressure was statistically significantly higher than baseline. Similarly, heart rate showed a significant increase from baseline following discontinuation of dexmedetomidine. Starting dexmedetomidine was not associated with a significant difference in the dosing of opiates or benzodiazepines. Comfort scores were significantly lower at 2 and 72 hours of dexmedetomidine infusion. After stopping dexmedetomidine, the comfort score for patients at 1 hour was statistically higher than for patients at cessation of the infusion. Thirty percent of patients who were taken off dexmedetomidine, whether weaned or abruptly stopped, had withdrawal symptoms and scores recorded with agitation, tremor, and decreased sleep being most prominent. Conclusions: Hemodynamic effects of dexmedetomidine did not limit long-term use in this diverse population. After the addition of dexmedetomidine, opioid and benzodiazepine doses did not significantly escalate, and patients were more comfortable as evidenced by decreasing comfort scores. Withdrawal from dexmedetomidine may be an issue and manifests as agitation, tremors, and decreased sleep. (Pediatr Crit Care Med 2014; 15:706-714) Key Words: benzodiazepines; critically ill; dexmedetomidine; opiates; pediatrics; prolonged infusion; withdrawal S edation in the PICU is vital for patient comfort and to facilitate care delivery. The use of dexmedetomidine hydrochloride (Precedex; Hospira, Lake Forest, IL), a selective α2-adrenoreceptor agonist, has increased in pediatrics as an adjunct to traditional sedation regimens and has become increasingly used as a primary sedative. The therapeutic effects of dexmedetomidine are mediated throughout the CNS: with the sedative and anxiolytic effects resulting from its activity in the locus ceruleus and the analgesic effects from the dorsal horn of the spinal cord (1) (2) (3) . These actions result in sedation, anxiolysis, and analgesia coupled with minimal concern for respiratory depression (3) . Becasue of its sympatholytic activity, the most significant adverse reactions associated with dexmedetomidine use are hypotension and bradycardia (2) .
Despite its popularity in the pediatric population, dexmedetomidine only has Food and Drug Administration approval for use in adults for up to 24 hours. Most data concerning pediatric use of dexmedetomidine remain centered on the use for less than 72 hours (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . There are few reports and case studies with small subject numbers describing the safety of dexmedetomidine with average use longer than 72 hours (17) (18) (19) (20) (21) (22) (23) , and fewer that highlights possible withdrawal and rebound symptoms (17, 18, 23) .
Our original dexmedetomidine policy at Seattle Children's Hospital, Seattle, WA, limited its use to 24 hours. As comfort increased with the use of the drug and its known side effects, the use expanded beyond these confines. This shift in clinical practice and experience with agitation after discontinuation of dexmedetomidine infusions prompted us to design this study to describe the hemodynamic variables, comfort scores, opioid and benzodiazepine use, and withdrawal symptoms during initiation, after 72 hours of use and up to 48 hours after discontinuation of dexmedetomidine.
MATERIALS AND METHODS

Study Design and Setting
The study was approved by the Institutional Review Board of Seattle Children's Hospital, which waived the need for informed consent. We performed a retrospective, observational study of patients in the PICU, cardiac ICU, and neonatal ICU at Seattle Children's between December 1, 2008, and December 1, 2010. Unit protocols at the time of this study included starting dose of 0.2 μg/kg/hr, max dose of 0.7 μg/kg/hr, and use for up to 48 hours unless approved by the unit medical director for longer duration.
Study Population
We included all patients less than 21 years old who had received a continuous infusion of dexmedetomidine longer than 72 hours. Exclusion criteria include greater than or equal to21 years, inability to obtain clinical information, or discontinuation of dexmedetomidine for any length of time during the first 72 hours. Patients were identified using our information technology database, discern analysis, that enabled us to identify patients with pharmacy charges for dexmedetomidine use longer than 72 hours.
Data Collection
Each patient's record was searched for major diagnosis and surgical procedures. Indication for starting dexmedetomidine, initiation and discontinuation times, initial and maximum dose, duration of use, and the utilization of dexmedetomidine wean were recorded. Blood pressure and heart rate (HR) were recorded for each patient at initiation (considered baseline), 30 minutes and 1, 2, and 72 hours of use, as well as at discontinuation, 30 minutes and 1, 2, 4, 24, and 48 hours after discontinuation. These intervals were chosen given the mean distribution half-life of approximately 10 minutes, duration of action of 4 hours, and the terminal elimination half-life of 2.7 hours (13, 22) .
Given recent work in our institution on sedation protocols by Deeter et al (24) , we used our established Seattle PICU Comfort Score to assess depth of sedation ( Table 1) . This sedation protocol was used in both the PICU and the cardiac ICU (CICU), whereas the newborn ICU (NICU) had an adjusted regimen. The typical progression of sedation in the PICU and CICU was opioid infusion and as needed intermittent benzodiazepine dosing. If increased sedation was needed, our sedation protocol instructed the addition of a benzodiazepine infusion. After this addition, it was physician preference whether to add a dexmedetomidine infusion or to increase both opioid and benzodiazepine infusion doses. The NICU protocol was similar with the exception that benzodiazepine infusions were not recommended.
Dexmedetomidine infusions were noted to either be weaned off or stopped abruptly. There was not a dexmedetomidine unit protocol or common practice at the time of this study. In regards to opioid and benzodiazepine weaning, it was unit practice to stop the infusions abruptly if on for less than 5 days or wean daily by 20% of the maximum daily dose every day if on for 5-10 days. For those on for greater than 10 days, the opioid and benzodiazepine infusions were typically weaned by 10% on alternating days. However, there was variability based on provider preference and patient tolerance of wean. There was no protocol in place directing which agent should be weaned or discontinued first. However, dexmedetomidine was typically discontinued first, but there was variability among providers. Withdrawal scores were assessed using the Opioid and Benzodiazepine Withdrawal Score (25) . Withdrawal scores were assessed on any patient receiving any form of opioid or benzodiazepine for greater than 5 days or if there was provider concern of withdrawal symptoms during the weaning of sedation.
Daily total opioid and benzodiazepine dose from the day before dexmedetomidine initiation to 48 hours after dexmedetomidine discontinuation was recorded and calculated as intravenous morphine and lorazepam equivalents. To assess significance of hemodynamic variability, vasoactive medication dosing was recorded at initiation, throughout dexmedetomidine administration, and after discontinuation. The use of atropine for bradycardia or saline bolus for hypotension within 4 hours of dexmedetomidine initiation was recorded. The addition of any antihypertensive within 48 hours after dexmedetomidine discontinuation and the addition of clonidine at any time during dexmedetomidine use were also noted.
Statistical Analysis
Basic descriptive statistics for patient characteristics are presented as proportions for categorical variables and median and range for continuous variables. Paired-sample t tests were used to estimate the mean difference in blood pressure, HR, and comfort score after initiation and discontinuation of dexmedetomidine at the various time points noted above. Wilcoxon matched-pairs signed-rank tests were used to compare daily total cumulative opiate and benzodiazepine dosing. Statistical analyses were performed using Excel and Stata software, version 10 (StataCorp LP, College Station, TX).
RESULTS
Patients who received dexmedetomidine for greater than or equal to 72 hours numbered 114. After excluding 16 patients (14 had dexmedetomidine paused during the 72 hours, and two patients for whom we could not locate clinical information), 98 remained for analysis. Of these 98 patients, 11 died while on dexmedetomidine. These patients did not contribute data pertaining to discontinuation of dexmedetomidine and withdrawal symptoms. Median age was 3.8 years with nearly even gender distribution ( Table 2 ). Forty six of the patients were treated in the PICU, 13 in the NICU, and 39 in the CICU. Sixty-five percent had undergone a surgical procedure, predominantly cardiac surgery ( Table  3) . Most children (92%) were started on dexmedetomidine for increased sedation need. Median duration of dexmedetomidine use was 141 hours ( Table 4) . Eleven of 98 patients died while on dexmedetomidine, and upon review it was felt that dexmedetomidine was not a contributing factor to these deaths. Of these patients, the median length of dexmedetomidine infusion was 336 hours ( Table 5 ). Of the remaining 87 patients, 52 (60%) were extubated while on dexmedetomidine, 30 (34%) remained intubated after dexmedetomidine discontinuation, three were never intubated, and two had pre-existing tracheostomies. Sixty-three (72%) of the 87 patients were weaned off dexmedetomidine while 24 (28%) had infusions stopped abruptly. Weaning was not dictated as a policy, and the choice to wean off dexmedetomidine infusion versus stop abruptly was made by the attending physician, in conjunction with the clinical pharmacist. Because of the lack of a weaning policy for dexmedetomidine, the weaning regimen was not standard and varied widely. Starting dose of dexmedetomidine for all patients was 0.2 μg/kg/hr and in 90 patients (92%) the dose increased to the unit maximum 0.7 μg/ kg/hr during their course. Eighty-five patients (87%) increased to the unit maximum dose within the first 24 hours of dexmedetomidine infusion. Two patients received infusions beyond 0.7 μg/kg/hr (1 and 1.5 μg/kg/hr) both of whom were on dexmedetomidine for greater than 30 days.
A statistically significant decrease in systolic blood pressure (SBP) from baseline was seen at 1, 2, and 72 hours after initiation of dexmedetomidine (p = 0.022, 0.004, 0.027, respectively) ( Table 6) . Diastolic blood pressure (DBP) did not change significantly with initiation and prolonged use. HR dropped significantly from baseline at 1, 2, and 72 hours after initiation (p ≤ 0.001 for each comparison). Because of hypotension, seven of 98 patients (7%) received a saline bolus within 4 hours of starting the dexmedetomidine infusion. Atropine was never required. No patients had the dexmedetomidine infusion stopped becasue of hemodynamic instability. Vasoactive infusions (including milrinone, epinephrine, dopamine, dobutamine, vasopressin, nitroprusside, nicardipine, and esmolol) were recorded during initiation of dexmedetomidine, and there was no statistically significant change in these infusions.
After cessation of the dexmedetomidine infusion, SBP rose statistically significantly higher at 1, 4, and 24 hours after discontinuation (p = 0.027, 0.034, 0.028, respectively) ( Table 7) . Discontinuation of dexmedetomidine was associated with a higher DBP at 30 minutes and 4 hours after infusion (p = 0.005 Antihypertensive added within 48 hr after dexmedetomidine, n (%)
(10)
Saline bolus within 4 hr, n (%) 7
Atropine used within 72 hr, n (%) 0 (0)
Data expressed are median and range except where specified.
and 0.006). HR was significantly higher at 30 minutes and 2, 4, 24, and 48 hours after infusion (p = 0.01, 0.006, <0.001, 0.002, 0.03, respectively). No statistically significant change was made to vasoactive infusions after stopping dexmedetomidine. Antihypertensives, excluding clonidine, were started in nine of 87 patients (10%) within 48 hours of discontinuing dexmedetomidine; however, six of those patients had cardiac lesions that would typically be treated with antihypertensives. Fifteen of 87 patients (17%) received clonidine at the time of dexmedetomidine discontinuation. Five of those patients (33%) received clonidine before initiation of dexmedetomidine as this was a baseline medication before hospitalization, whereas the other 10 patients (67%) had clonidine added to facilitate tapering of dexmedetomidine and to attenuate withdrawal symptoms. Our data did not show significantly lower doses of opioids or benzodiazepines after initiation of dexmedetomidine ( Table 8) . Opioid use on the day before dexmedetomidine initiation was statistically significantly lower when compared with the day of dexmedetomidine initiation (p = 0.015). Opioid use 24 and 48 hours after discontinuation of dexmedetomidine was also statistically significantly lower when compared with dosing on the day of discontinuation (p = 0.008 and 0.0001) ( Table 9 ). The only statistically significant lowering in benzodiazepine dose was seen at 48 hours after discontinuation of dexmedetomidine (p = 0.022). The comfort scores were significantly lower at 2 and 72 hours of dexmedetomidine infusion (p = 0.007, 0.001, respectively) ( Table 6 ). After stopping dexmedetomidine, the comfort score at 1 hour was statistically higher than at cessation of the infusion, indicating a less sedated patient (p = 0.030) ( Table 7) .
Once started on dexmedetomidine infusion, 12 of 98 of the patients (12%) required no increase in opioid daily dosing. Of the 86 patients who required increase in their opioid dosing after initiation of dexmedetomidinedexmedetomidine, 20 (23%) reached their maximum dose of opioid on day 1 of DEX infusion, 18 (21%) on day 2, 14 (16%) on day 3, seven (8%) on day 4, and six (7%) on day 5 of dexmedetomidine infusion. The median increase from baseline opioid dose was 33%. Nineteen (22%) reached their maximum dose of opioid on or after day 6 of dexmedetomidine with a median dose increase of 78% from baseline. The median length of treatment for patients who had no increase in opioid after dexmedetomidine infusion was started at 5 days. For those who had their maximum opioid dose on days 2-5 of dexmedetomidine infusion, the median length of treatment was 6 days. For the patients who reached their maximum opioid dose on or after day 6 of dexmedetomidine infusion, the median length of treatment was 14 days. Two patients were weaned off of all opioids before discontinuation of dexmedetomidine infusion, and the median length of treatment for this group was 4.5 days. Once off of dexmedetomidine infusion, 22 of 89 patients (25%) required an increase in their daily opioid dose (14% dose increase), whereas 65 (66%) continued to wean off of opioids.
Benzodiazepine dosing was affected similar to opioid dosing for patients on dexmedetomidine infusions, except that more patients were able to wean off of benzodiazepines before discontinuation of dexmedetomidine infusions (14 of 89, 16%). Twenty-four percent of patients (24 of 98) required no increase in benzodiazepine daily dose after initiation of dexmedetomidine infusion. Of the 74 patients who required increase in their benzodiazepine dosing after initiation of dexmedetomidine, nine (12%) reached their maximum dose of benzodiazepine on day 1 of dexmedetomidine infusion, 12 (16%) on day 2, six (8%) on day 3, 13 (18%) on day 4, and nine (12%) on day 5 of dexmedetomidine infusion. The median increase from baseline benzodiazepine dose was 42%. Twenty-five (34%) reached their maximum dose of benzodiazepine on or after day 6 of dexmedetomidine with a median increase of 61% from baseline. The median length of treatment for patients who had no increase in benzodiazepine after dexmedetomidine infusion was started at 6 days. For those who had their maximum benzodiazepine dose on days 2-5 of dexmedetomidine infusion, the median length of treatment was 5 days. For the patients who reached their maximum opioid dose on or after day 6 of dexmedetomidine infusion, the median length of treatment was 13 days. After discontinuation of dexmedetomidine infusion 25 of 89 patients (28%) required an increase in the daily benzodiazepine dose (21% increase), whereas 49 (56%) continued to wean. Fourteen patients (16%)
were weaned off of benzodiazepine before dexmedetomidine infusion was discontinued, and the median length of treatment for these patients was 5 days.
Of the 87 patients who did not die, 26 (30%) had withdrawal scores and symptoms recorded, the other 61 patients were not formally assessed for withdrawal symptoms (Table 10) . These patients had a median duration of use of 178 hours when compared with that of 123 hours for those without withdrawal scores recorded. Of the 26 patients, 18 (69%) were weaned off of dexmedetomidine. The most common withdrawal score at 24 and 48 hours after discontinuation was 11 (range, 0-16). Of patients weaned off dexmedetomidine, the most common withdrawal score at 24 hours was 3 (2-14) and at 48 hours was 4 (0-12). Seventeen of 26 patients (65%) had agitation recorded as a withdrawal symptom, 10 of 26 (38%) had tremors, and 14 of 26 (54%) exhibited decreased sleep. Patients who exhibited withdrawal symptoms were treated with the increase in opioid or benzodiazepine dosing or had clonidine added if dexmedetomidine withdrawal was a concern to the provider.
DISCUSSION
We report the use of dexmedetomidine infusion in critically ill infants and children at doses of 0.2-0.7 μg/kg/hr for a median duration of 141 hours. The major findings from our study include 1) prolonged infusions of dexmedetomidine can be tolerated safely and are associated with minimal clinically significant hemodynamic effects, 2) dexmedetomidine infusions may decrease the overall opioid and benzodiazepine burden, and 3) prolonged infusions of dexmedetomidine may be associated with rebound tachycardia, hypertension, and withdrawal symptoms with rapid discontinuation, suggesting a need for weaning of the infusion.
Many adult studies have demonstrated the safety of dexmedetomidine use longer than 24 hours (26) (27) (28) (29) , and limited pediatric studies show a similar safety profile of long-term Data expressed are total number and percentage except when specified. dexmedetomidine to that of adults (8, 10, 12, 20, 22) . Our study mirrors the findings of both the adult and the pediatric data. Known hemodynamic effects, such as decrease in HR and blood pressure, were noted on initiation of dexmedetomidine. However, only seven patients (7%) received normal saline bolus and none needed adjustment in their cardiovascular medications, suggesting that the clinical significance of the hemodynamic changes is minimal and long-term infusion is well tolerated. This could be because of our avoidance of a loading dose or the overall low infusion dose when compared with current practice. Unlike other pediatric studies (26, 30, 31) , the only statistically significant decrease in opioid and benzodiazepine use was after discontinuation of dexmedetomidine, suggesting an overall wean off of sedative medications. The majority of our patients did require an increase in opioid (88%) and benzodiazepine (76%) dosing, despite the initiation of dexmedetomidine infusion. We argue that this could be anticipated on the day of dexmedetomidine initiation because most of our patients were treated with dexmedetomidine because of increased sedation needs. Of the patients who reached their maximum opioid and benzodiazepine doses after day 1 of dexmedetomidine infusion, 24 (of total 41, 59%) had an initial decrease in opioid and benzodiazepine need. We speculate that the initial decline, then subsequent increase, could be because of tachyphylaxis to either the traditional sedation regimen or to the dexmedetomidine infusion. Further suggesting this phenomenon are those patients who reached their maximum opioid and benzodiazepine dose after 6 days of dexmedetomidine infusion as they were on dexmedetomidine twice as long as the patients and had a higher increase opioid and benzodiazepine dosing.
With one quarter of our patients requiring increased opioid and benzodiazepine doses after dexmedetomidine discontinuation, this could suggest that this is because of the lack of dexmedetomidine effect. This must be noted cautiously, however, as it may indicate treatment for withdrawal symptoms. Comfort scores were significantly lower with initiation of dexmedetomidine, suggesting that dexmedetomidine did aid in increasing patient comfort. It should be noted that during our study, the average maximum infusion dose was 0.7 μg/kg/hr, which, when compared with more recent practice, would be considered low dose. This may explain our lack of statistically significant changes in opioid and benzodiazepine daily dosing, given that there are data supporting high-dose dexmedetomidine infusion when compared with low-dose when attempting to decrease opioid burden (32) .
Of the previous pediatric studies noted, the one by Czaja and Zimmerman (12) most closely resembles our study in number and unit use of dexmedetomidine infusion. Interestingly, this study showed a higher rate of hemodynamic side effects and a statistically significant decrease in opioid and benzodiazepine use with the initiation of dexmedetomidine infusions when compared with our work. Possible reasons for this difference could be the earlier date of their study in general, which may have been associated with less experience with the drug and less tolerance of the hemodynamic side effects, as noted in their discussion. Dexmedetomidine use and the hemodynamic effects had been well described by 2008, and this could have increased comfort among our providers to "wait out" the decrease in HR and blood pressure. It is also possible that by design of our study, we selected patients who better tolerated the drug, as they had to be on the dexmedetomidine infusion for greater than or equal to 72 hours, and did not include study patients who may have had more hemodynamic side effects causing cessation of the dexmedetomidine infusion earlier.
Their study also shows an impressive decrease of opioid and benzodiazepine burden for their patients while on dexmedetomidine infusion (36% and 42%, respectively), which was not found in our study. There are some notable differences in our study that may have contributed to this discrepancy. First, during the period of time of the study of Czaja and Zimmerman (12) , the use of dexmedetomidine in their unit was specifically used primarily with the goal to decrease opioid and benzodiazepine doses in patients requiring high doses of benzodiazepines and/or opioids, cycling on and off dexmedetomidine typically every 24 to 48 hours (J. J. Zimmerman, personal communication, 2012). In addition, 52% of the patients in the study of Czaja and Zimmerman (12) were on dexmedetomidine to decrease longer acting sedative agents to facilitate extubation as opposed to 5% in this study. Thus, in the study of Czaja and Zimmerman (12) , the goal of using dexmedetomidine was to decrease infusions of benzodiazepines and/or opioids, whereas during the timeframe of our study dexmedetomidine was primarily added earlier to the sedation regimen to prevent significant escalation of opioids and benzodiazepines without an explicit agenda to wean these actively. However, as noted above, there is a suggestion to support that dexmedetomidine infusion can act synergistically and decrease the overall burden of both of these drugs as there was not a statistically significant escalation of doses after starting dexmedetomidine in our study. We did show an increase in opioid and benzodiazepine daily dose in approximately one quarter of our patients once off dexmedetomidine infusion, similar to the study of Czaja.
Limited data about withdrawal and rebound hypertension or tachycardia after dexmedetomidine use longer than 72 hours. Pediatric data suggest a trend toward rebound and withdrawal symptoms with increased use (17, 19, 23, 25) . Of the studies that report no concerns for withdrawal symptoms (5, 7, (20) (21) (22) 31) , two weaned the patients off dexmedetomidine (21, 22) and one started 30% of their patients on clonidine (31), which could explain the lack of withdrawal symptoms.
Our study raises concern for withdrawal and rebound. Both SBP and DBP increased significantly after discontinuation of dexmedetomidinedexmedetomidine and this increase persisted over the first 24 hours. HR also significantly increased over the first 48 hours after discontinuation. Yet, despite the statistically significant increase, treatment with either new antihypertensive or clonidine was prescribed for only 21% of our patients. The addition of clonidine was specifically for amelioration of withdrawal symptoms and was started at the discretion of the provider. It is possible that these patients would have experienced withdrawal or rebound symptoms if not started on clonidine. Antihypertensive medication, excluding clonidine, was started in nine patients (10%) after 36 hours of hypertension. In all of these patients, increased sedation was trialed for concern of discomfort causing hypertension. Again, it is worth noting that six of these nine patients would have been started on an antihypertensive medication given their cardiac lesion and not necessarily in response to hypertension.
We acknowledge that at the cessation of dexmedetomidine infusion, patients were presumably improved from a clinical standpoint leading to higher HR and blood pressure reflected by a less sedated patient. We did find that patients had increased opioid use in 25% of the cases and benzodiazepine in 28% of the patients. Whether this is because of increased discomfort, withdrawal not specifically noted or increasing BP and HR from dexmedetomidine discontinuation can only be speculated. Despite this question, our findings suggest that although rebound hypertension and tachycardia are seen with cessation of long-term dexmedetomidine infusion, treatment with clonidine or other antihypertensive is rarely required, further illustrating the safety of long-term infusions.
Our study confirmed the risk of withdrawal symptoms following long-term dexmedetomidine infusion. Of our patients, 30% had recorded withdrawal scores and symptoms that suggested a withdrawal phenomenon from dexmedetomidine infusions. These patients had a higher median infusion duration (178 vs 123 hr). Symptoms recorded were similar to those seen in previous case reports and included agitation, tremors, and decreased sleep. The symptoms most commonly recorded are similar to delirium seen in ICU patients. It was our unit practice to "normalize" the patients schedule as much as possible when concerns for delirium were noted. This included a schedule set by nursing and child life, normal daytime and nighttime activities as possible, including light adjustment, music therapy, and activity in room. Despite these efforts, it is impossible to say with certainty that these patients were not experiencing a degree of delirium. However, we speculate that this question can be raised with any sedation withdrawal evaluation, not just dexmedetomidine withdrawal. We acknowledge that we cannot completely conclude that the withdrawal symptoms were not from opioid or benzodiazepine because the majority of the patients were on these infusions as well at time of dexmedetomidine discontinuation. Our study suggests that weaning the dexmedetomidine infusion, which happened in 69% of the patients with withdrawal scores recorded, was associated with lower withdrawal scores and less use of rescue treatment.
The retrospective nature of the study is susceptible to design flaws and bias. We are unable to differentiate between the use of dexmedetomidine or other reasons (eg, other sedation and patient condition) as the cause of hemodynamic and sedative effects or withdrawal symptoms. Despite being one of the larger pediatric studies, which was not limited to just one subset of PICU patients, it may not be generalizable to all PICU patients given other unit sedation and analgesia practices. Specifically, this study was done while our unit policies and practice were to keep the maximal dose of dexmedetomidine infusion at 0.7 μg/kg/hr. We acknowledge that this is not the most recent practice in either our unit or many others around the country. We can only speculate that our findings of withdrawal phenomenon would be augmented by higher doses of dexmedetomidine infusion, but this study cannot speak specifically to this. It is also possible that concerning hemodynamic changes may be augmented on higher dose of dexmedetomidine infusion. Our study recorded change from baseline hemodynamics as the parameter of significance. This is not ideal because it did not recognize the age appropriate hemodynamic parameters, which patients may have deviated from. Patients were also used as their own controls, limiting our ability to make any firm conclusions about dexmedetomidine use as a comparison with no dexmedetomidine use. We acknowledge that there was self-selection of patients who tolerated dexmedetomidine well enough to be treated for greater than or equal to 72 hours given that our records show that 459 patients were treated with any amount of dexmedetomidine during this 2-year time period. Finally, it was not our routine unit practice to record withdrawal scores during dexmedetomidine discontinuation. Scores could also reflect opioid or benzodiazepine withdrawal.
CONCLUSIONS
We have evaluated the use of long-term dexmedetomidine administration in a diverse population of critically ill infants and children 0-21 years old. On the basis of our findings, we conclude that dexmedetomidine is effective and safe for longterm use in the PICU. Attention to known adverse hemodynamic effects while on dexmedetomidine is necessary, but need for treatment is rare. Comfort and sedation is improved with dexmedetomidine, and a decrease in the overall opioid or benzodiazepine burden is probably given that there was not a significant escalation of benzodiazepine or opioid dosing after starting dexmedetomidine. Vigilance for tachycardia and hypertension at dexmedetomidine discontinuation is appropriate; however, these rarely require treatment. The most prominent withdrawal symptoms include agitation, tremors, and decreased sleep and may be ameliorated by weaning dexmedetomidine.
